Pricing Log in Create free account

Mesoblast Limited (MESO) vs Trevi Therapeutics, Inc. (TRVI)

Mesoblast Limited and Trevi Therapeutics, Inc. are both Biotechnology companies. Mesoblast Limited and Trevi Therapeutics, Inc. are of similar size ($1.8B and $1.8B). Trevi Therapeutics, Inc. has the higher net margin (0.00% vs −1,091.7%) and the lower return on invested capital (−1,412.1% vs 0.00%). Across the 13 metrics below, Trevi Therapeutics, Inc. leads on 7 and Mesoblast Limited on 6.

Valuation

Metric MESO TRVI Biotechnology median
P/E n/m n/m 10.60
P/S 147.54 n/m 9.40
P/B 1.93 6.93 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 147.13 n/m 9.02
Earnings yield (7.87%) (2.39%) (32.88%)
Free cash flow yield (7.62%) (2.37%) (23.13%)

Profitability

Metric MESO TRVI Biotechnology median
Gross margin (269.72%) 0.00% 68.51%
Operating margin (826.28%) 0.00% 0.00%
Net margin (1,091.71%) 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (19.66%) (51.96%)
Return on assets 0.00% (18.97%) (46.06%)
Return on invested capital 0.00% (1,412.11%) 0.00%

Growth

Metric MESO TRVI Biotechnology median
Revenue growth (TTM) (26.54%) — 6.76%
EPS growth (last fiscal year) 48.24% 31.91% 29.88%
Revenue growth, 5-year CAGR 74.39% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MESO TRVI Biotechnology median
Debt to equity 0.22 0.00 0.00
Current ratio 1.58 37.28 4.97
Net debt to EBITDA (0.67) 3.83 1.01

Dividend

Metric MESO TRVI Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric MESO TRVI Biotechnology median
Market cap 1.83b 1.83b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack